1/26
Comprehensive vocabulary flashcards covering the core concepts, genetic variations, drug metabolism phenotypes, and clinical applications from the lecture on Pharmacogenomics.
Pharmacogenomics
The intersection of pharmacology and genetics that studies how variations in an individual's genetic makeup affect the body's response to medications, enabling the prediction of therapeutic response.
Pharmacokinetics
The process describing how a drug is absorbed, distributed, metabolized, and excreted by the body (ADME); fundamentally, what the body does to the drug.
Pharmacodynamics
The biochemical and physiological effect of a drug on the body; fundamentally, what the drug does to the body.
Pharmacogenetics
The study or clinical testing of genetic variation that assists in differentiating individual patient responses to drugs.
Genomics
The study of the entire set of genetic instructions (DNA) found within a cell.
Polymorphism
A DNA sequence variant that is present in >1% of the population.
Mutation
A DNA sequence variant that is present in <1% of the population.
Alleles
Two different versions, or alternate sequences, of the same gene localized at any position on a chromosome.
Linkage Disequilibrium
A non-random association of alleles at two or more loci descendant from a single ancestral chromosome, causing them to be co-transmitted more or less often than expected by chance alone (usually due to close physical proximity).
Genotype
The total hereditary material of an individual, specifically referring to the pair of alleles carried for a given gene.
Phenotype
The observable set of characteristics or clinical presentation of an individual resulting from a particular genotype.
Haplotype
A set of closely linked genetic markers present on one chromosome that tend to be inherited together without being easily separated.
Restriction Fragment Length Polymorphism (RFLP)
A DNA fragment length polymorphism (FLP) caused by insertions or deletions of base sequences that alter restriction endonuclease cleavage loci, altering resulting fragment lengths.
Repeat Sequence Polymorphism (RSP)
Genetic variation manifested by differences in the number of copies of repetitive DNA sequences, particularly short tandem repeats (STRs) in satellite or microsatellite DNA.
Single Nucleotide Polymorphism (SNP)
The most common form of genetic variation in humans, occurring roughly once every 300–3,000 base pairs, involving single-base substitutions (most frequently at CG sites), insertions, or deletions.
Poor Metabolizer (PM)
An individual carrying two reduced-function or null alleles for a drug-metabolizing enzyme, leading to drug accumulation and toxicity with active parent drugs, or lack of efficacy with pro-drugs.
Ultra-Rapid Metabolizer (UM)
An individual with genetic variants causing abnormally high enzymatic clearance, which can lead to reduced therapeutic efficacy for active drugs or excessive toxicity with pro-drugs.
Personalized Medicine
The tailoring of medical treatment to specific patient characteristics using genetic, protein, and environmental information to classify individuals into distinct subpopulations that differ in disease susceptibility or treatment response.
VKORC1
Vitamin K epoxide reductase subunit 1; the molecular drug target of warfarin whose promoter polymorphism (c.-1639G>A or 1173 C>T) increases sensitivity to warfarin and lowers dose requirements.
CYP2C9
A cytochrome P450 enzyme that metabolizes warfarin; variants CYP2C92 and CYP2C93 show reduced enzymatic activity (12% and 5% of wild type, respectively), increasing bleeding risks and lowering dose requirements.
CYP2C19
A polymorphic drug-metabolizing enzyme that metabolizes proton pump inhibitors such as omeprazole, containing loss-of-function alleles (*2, *3) as well as an increased-activity allele (*17).
HLA-B*5701
A human leukocyte antigen allele strongly associated with severe, potentially fatal hypersensitivity reactions to the antiretroviral medication abacavir.
Abacavir
A nucleoside reverse transcriptase inhibitor used in combination antiretroviral therapy for HIV that requires mandatory pre-therapy screening for the HLA-B*5701 allele to prevent life-threatening hypersensitivity.
Nortriptyline
A tricyclic antidepressant metabolized by CYP2D6 with highly genotype-dependent dosing requirements, ranging from 10–20mg⋅d−1 in poor metabolizers to >500mg⋅d−1 in ultra-rapid metabolizers.
AmpliChip CYP 450
A commercially available pharmacogenomic diagnostic test manufactured by Roche/Affymetrix designed to identify CYP variations to individualize drug dosing.
AlloMap
A commercial diagnostic test from XDx used to identify heart transplant recipients with stable allograft function to inform clinical management decisions.
Trofile
A diagnostic assay produced by Monogram/Pfizer to test for HIV-1 coreceptor tropism as a companion test for maraviroc therapy.